	US 12,186,325 B2
	Treatment and prevention of premature ejaculation (PE)
Daniel Drai, Givataim (IL)
Assigned to SEROJAC PME HANDELS GMBH, Vienna (AT)
Appl. No. 17/290,038
Filed by SEROJAC PME Handels GmbH, Vienna (AT)
PCT Filed Oct. 30, 2019, PCT No. PCT/EP2019/079584 § 371(c)(1), (2) Date Apr. 29, 2021, PCT Pub. No. WO2020/089261, PCT Pub. Date May 7, 2020.
Claims priority of application No. 18203410 (EP), filed on Oct. 30, 2018.
Prior Publication US 2021/0401852 A1, Dec. 30, 2021
Int. Cl. A61K 31/55 (2006.01); A61K 31/475 (2006.01); A61P 15/00 (2006.01)

CPC A61K 31/55 (2013.01) [A61K 31/475 (2013.01); A61P 15/00 (2018.01)]

14 Claims

1. A method for treating premature ejaculation in a subject in need thereof, the method comprising:

administering to the subject an effective amount of a pharmaceutical composition comprising clomipramine (3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine) or a pharmaceutically acceptable salt form thereof and yohimbine (17α-hydroxy-yohimban-16α-carboxylic acid methyl ester) or a pharmaceutically acceptable salt form thereof wherein the composition comprises clomipramine in a range of from 5 to 150 mg, yohimbine in a range of from 5 to 150 mg, and clomipramine and yohimbine are present in a molar ratio in a range of from 0.2 to 5.